Intraocular Properties of Urokinase-Derived Antiangiogenic A6 Peptide in Rabbits

To investigate the intraocular properties of an antiangiogenic peptide, Angstrom6, a total of 70 New Zealand rabbit eyes were used. For the toxicity study, 0.05 mL of 0.459 M or 0.148 M Angstrom6 was injected intravitreally; right eyes received Angstrom6, and left eyes received a vehicle. Serial intraocular pressure measurement, slit lamp, and indirect ophthalmoscopy were performed. The rabbit eyes were evaluated by fluorescein angiography, electroretinography, and histology after the scheduled sacrifice. The pharmacokinetics of an intravitreal Angstrom6 (0.05 mL of 0.488 M) and a subtenon Angstrom6 (0.5 mL of 0.305 M) injection was studied. There was no toxicity observed following the 0.148 M Angstrom6 intravitreal injections. In 2 eyes with a 0.459 M Angstrom6 intravitreal injection, focal retinal pigmentary change was observed at the injection site, which was contacted by the hyperosmolar drug bolus. Choroidal Angstrom6, following the intravitreal injection, remained therapeutic (greater than or equal to10 muM) for 72 hours. The vitreous half-life was 19.4 hours. Choroidal concentrations following the subtenon injection were minimal. The low choroidal concentrations observed may relate to the polar nature of Angstrom6. More hydrophobic analogs of Angstrom6 are likely to cross the retina more efficiently. However, in diseased eyes, in the area of choroidal neovascularization (CNV), the fluid-filled, damaged, edematous retina may permit the drug to enter the choroid in higher concentrations.